Dihydroboldenone

Dihydroboldenone, usually called DHB or 1-testosterone, is an anabolic steroid discussed for strength and a harder, more muscular look. People describe anything from useful gains to little change, with injection pain sometimes outweighing the benefit. It is different from testosterone and Equipoise.

A separate steroid related to boldenone. Boldenone is the compound behind EQ or Equipoise. DHB is its chemically reduced relative, also called 1-testosterone; that name does not mean ordinary testosterone. Comparisons such as 'EQ 2.0' describe someone's experience, not interchangeable drugs.

Cypionate oil injections dominate this discussion. The existing reports concern intramuscular oil injections, not a peptide powder that needs reconstitution. In a forum discussion, users distinguish DHB cypionate, which has an attached ester, from ester-free DHB base mentioned in pre-workout blends. A blend's name alone does not settle its ingredients or timing. DHB: base versus cypionate in a pre-workout question (Community discussion · Accessed 2026-09-30)

Source context — DHB: base versus cypionate in a pre-workout question: Form-identification discussion, not a verified blend composition or completed outcome log. Commercial source-review context. Direct Python request was forbidden; web tool subsequently exposed actual post and reply bodies. No historical supplement legality inferred.

Strength, fullness and a drier look. Users describe more visible veins and fuller muscles without the watery appearance they associate with some other steroids. One cut account reported retaining muscle while losing weight; another bulk account reported an 11-pound gain over 16 weeks. Both included testosterone, so neither isolates DHB's contribution. Compounds: DHB (Dihydroboldenone) (Community discussion · Accessed 2026-09-30)

The dramatic strength story has counterexamples. A comparison-thread user described stronger incline pressing alongside feverish symptoms and disabling pain. A different author found 400 mg/week barely noticeable and remained disappointed after increasing to 800 mg/week while changing other steroids. 'Tren lite' does not describe a predictable response. Compound Experience Thread: 1-Test, DHB, Dihydroboldenone (Community discussion · Accessed 2026-09-30) · Compounds: DHB versus Tren (Community discussion · Accessed 2026-09-30)

Painless does not necessarily mean feeling well. A MESO user reported no injection pain but flu-like fatigue after 2–4 weeks, even at 50 mg/week. Another described good cosmetic results without increased strength. These disagreements are more useful than treating the drug as universally mild or universally intolerable. DHB advice: differing benefit and fatigue reports (Community discussion · Accessed 2026-09-30)

Mental drive and irritability can appear in different accounts. The recent thread includes an account of drive without pain and another reporting lethargy and irritability. The older EQ comparison includes hopes of less anxiety; that preference does not establish a gentler mood response. DHB: recent dose, drive and pain accounts (Community discussion · Accessed 2026-09-30)

Source context — Compounds: DHB (Dihydroboldenone): Several steroids, changing testosterone, subjective body composition, unverified blood tests/product identity and confounding dehydration. Pain cannot identify a drug; apparent estrogen changes do not establish aromatase inhibition. No denominator supports prevalence claims.

Source context — Compound Experience Thread: 1-Test, DHB, Dihydroboldenone: Anonymous self-reports, deleted identities, unverified preparations and extensive co-use. Partner's female account is secondhand. Reply chains from one writer are one account; brewing advice is not reproduced. Exact publication date was not established from the opened relative timestamps.

Source context — Compounds: DHB versus Tren: Subjective comparative accounts, mixed stacks, unverified products, some deleted writers. A quoted wiki dose is a circulated chart claim, not an initiation instruction. Reposted pain anecdote acknowledged within the thread is not counted as another independent report. Exact date not inferred from relative timestamp.

Source context — DHB advice: differing benefit and fatigue reports: Commercially adjacent forum; unverified preparations, co-use and lab claims. Posts assert unsupported population percentages, liver mechanisms and steroid safety rankings; those assertions are excluded. eery's friends are secondhand rather than independently inspected cases.

Source context — DHB: recent dose, drive and pain accounts: Small sample in a commercially named steroid community; promotional context can bias reports. All benefit accounts involve other steroids. Saturation/CNS explanations are speculation. Planned 4–6-week add-on in OP is a question, not a completed course. Same-author mood follow-up is not another person.

300–500 mg/week, divided, appears in the existing injectable reports. This band summarizes community discussion, not a requirement or a safe ceiling. Smaller 'try it' amounts and divided weekly totals are also described; the original record does not specify one standard injection frequency.

70–210 mg/week in one recent account. The July 2026 user increased between these amounts while also using testosterone and Primobolan. This does not establish a minimum effective amount. DHB: recent dose, drive and pain accounts (Community discussion · Accessed 2026-09-30)

100–200 mg/week in a different thread. That writer described strong pumps but extreme lethargy above 150–200 mg/week. One person's threshold does not predict another's tolerability. Compounds: DHB versus Tren (Community discussion · Accessed 2026-09-30)

The dramatic strength story has counterexamples. A comparison-thread user described stronger incline pressing alongside feverish symptoms and disabling pain. A different author found 400 mg/week barely noticeable and remained disappointed after increasing to 800 mg/week while changing other steroids. 'Tren lite' does not describe a predictable response. Compound Experience Thread: 1-Test, DHB, Dihydroboldenone (Community discussion · Accessed 2026-09-30) · Compounds: DHB versus Tren (Community discussion · Accessed 2026-09-30)

Source context — DHB: recent dose, drive and pain accounts: Small sample in a commercially named steroid community; promotional context can bias reports. All benefit accounts involve other steroids. Saturation/CNS explanations are speculation. Planned 4–6-week add-on in OP is a question, not a completed course. Same-author mood follow-up is not another person.

Source context — Compounds: DHB versus Tren: Subjective comparative accounts, mixed stacks, unverified products, some deleted writers. A quoted wiki dose is a circulated chart claim, not an initiation instruction. Reposted pain anecdote acknowledged within the thread is not counted as another independent report. Exact date not inferred from relative timestamp.

Source context — Compound Experience Thread: 1-Test, DHB, Dihydroboldenone: Anonymous self-reports, deleted identities, unverified preparations and extensive co-use. Partner's female account is secondhand. Reply chains from one writer are one account; brewing advice is not reproduced. Exact publication date was not established from the opened relative timestamps.

Strength changes after a few weeks in some accounts. One user placed a marked incline-press increase in weeks 3–4; the existing record describes hardness comments in weeks 3–8. Those are different outcomes, not a guaranteed onset window. Compounds: DHB versus Tren (Community discussion · Accessed 2026-09-30)

'Saturation' is a separate community claim. A recent user reported strength after a few weeks, then claimed 5–6 weeks to saturate. That explanation was not a measured DHB accumulation study. DHB: recent dose, drive and pain accounts (Community discussion · Accessed 2026-09-30)

No dependable single-injection benefit window. The reports describe repeated use and changing training, diet and stacks. They do not establish how long one injection improves performance or how much muscle remains after stopping.

Cypionate: about 7 days versus 8–10 days in forum replies. Two posters give these separate estimates in the same thread. Neither supplies a DHB measurement. Half-life means the measured amount falling by half; it is not a duration of strength gains, soreness or drug-test detectability. Cycle Opinion/Advice wanted: differing cypionate half-life estimates (Secondhand community claim · Accessed 2026-09-30)

Source context — Compounds: DHB versus Tren: Subjective comparative accounts, mixed stacks, unverified products, some deleted writers. A quoted wiki dose is a circulated chart claim, not an initiation instruction. Reposted pain anecdote acknowledged within the thread is not counted as another independent report. Exact date not inferred from relative timestamp.

Source context — DHB: recent dose, drive and pain accounts: Small sample in a commercially named steroid community; promotional context can bias reports. All benefit accounts involve other steroids. Saturation/CNS explanations are speculation. Planned 4–6-week add-on in OP is a question, not a completed course. Same-author mood follow-up is not another person.

Source context — Cycle Opinion/Advice wanted: differing cypionate half-life estimates: No cited pharmacokinetic measurement; both values are community ester estimates. Forum displays sponsorship and commercial board representatives. Nearby blood-pressure, lethargy and break-calendar discussion concerns Superdrol, not DHB.

8–12 weeks in the existing record; longer accounts also appear. A recent testosterone, Primobolan and DHB account describes 18 weeks. These are histories, not optimal courses or evidence that longer use is safe. DHB: recent dose, drive and pain accounts (Community discussion · Accessed 2026-09-30)

Ten weeks or less was one user's preference. That writer limited courses because of repeated night sweats. It is an individual tradeoff, not a standard cycle limit. Compounds: DHB (Dihydroboldenone) (Community discussion · Accessed 2026-09-30)

Some stop before a planned course is finished. Pain reports describe abandoning use rather than completing a course. The inspected accounts do not establish a repeat-cycle calendar or standard recovery interval. Compounds: DHB versus Tren (Community discussion · Accessed 2026-09-30)

Source context — DHB: recent dose, drive and pain accounts: Small sample in a commercially named steroid community; promotional context can bias reports. All benefit accounts involve other steroids. Saturation/CNS explanations are speculation. Planned 4–6-week add-on in OP is a question, not a completed course. Same-author mood follow-up is not another person.

Source context — Compounds: DHB (Dihydroboldenone): Several steroids, changing testosterone, subjective body composition, unverified blood tests/product identity and confounding dehydration. Pain cannot identify a drug; apparent estrogen changes do not establish aromatase inhibition. No denominator supports prevalence claims.

Source context — Compounds: DHB versus Tren: Subjective comparative accounts, mixed stacks, unverified products, some deleted writers. A quoted wiki dose is a circulated chart claim, not an initiation instruction. Reposted pain anecdote acknowledged within the thread is not counted as another independent report. Exact date not inferred from relative timestamp.

Stacks blur both benefits and adverse effects. Testosterone is a recurring companion; EQ also appears in bulk discussions. A harder look, strength changes or worse bloodwork cannot automatically be credited to DHB when several androgens and training variables change together.

+ testosterone: A recurring companion in the saved accounts. Co-use prevents attributing gains, mood changes or laboratory results to DHB alone. [community]

+ EQ in some bulk logs — overlapping androgen. [community]

70–210 mg/week in one recent account. The July 2026 user increased between these amounts while also using testosterone and Primobolan. This does not establish a minimum effective amount. DHB: recent dose, drive and pain accounts (Community discussion · Accessed 2026-09-30)

Source context — DHB: recent dose, drive and pain accounts: Small sample in a commercially named steroid community; promotional context can bias reports. All benefit accounts involve other steroids. Saturation/CNS explanations are speculation. Planned 4–6-week add-on in OP is a question, not a completed course. Same-author mood follow-up is not another person.

Pain can start after an initially comfortable injection. One account describes swelling and fever after six hours; another describes pain appearing on day three. This is adverse-effect onset, separate from muscle or strength changes. Compound Experience Thread: 1-Test, DHB, Dihydroboldenone (Community discussion · Accessed 2026-09-30)

Pain and swelling can persist for days or longer. One user reported 6–7 days of swelling after an injection; another said painful knots took weeks to disappear. The earlier claim that pain resolves first after stopping is not supported as a shared sequence or recovery timetable. Compound Experience Thread: 1-Test, DHB, Dihydroboldenone (Community discussion · Accessed 2026-09-30)

PIP means post-injection pain; it cannot authenticate DHB. Painful and relatively painless reports appear side by side. Posters argue over carrier oils, solvents, individual sensitivity and mislabeled testosterone or boldenone. Warming oil and splitting injections circulate as workarounds, but users also report those approaches failing. None verifies the contents of a vial. Compounds: DHB versus Tren (Community discussion · Accessed 2026-09-30)

A harder look can coexist with worse health markers. A bulk report describes higher blood pressure, worse cholesterol and concern over kidney-test results, with dehydration and lifting complicating interpretation. The existing record also flags hematocrit, the proportion of blood occupied by red cells. Normal reported bloodwork in other users does not prove safety. Compounds: DHB (Dihydroboldenone) (Community discussion · Accessed 2026-09-30)

Androgenic effects matter beyond muscle. A partner's account describes voice changes and hair growth within three weeks at 50 mg/week in a woman. Hair-loss reports also differ between users. This is a secondhand adverse account, not a female dose recommendation or reassurance from someone else's lack of shedding. Compound Experience Thread: 1-Test, DHB, Dihydroboldenone (Community discussion · Accessed 2026-09-30)

Estrogen claims conflict. One user thought DHB lowered estrogen; another reported no such effect. The first also described breast symptoms after stopping DHB and reducing testosterone. Co-use and uncertain product identity prevent those histories from establishing DHB as an aromatase inhibitor or an estrogen-control plan. Compounds: DHB (Dihydroboldenone) (Community discussion · Accessed 2026-09-30)

U.S. Schedule III includes 1-testosterone. The federal list names delta-1-dihydrotestosterone, also called 1-testosterone, among anabolic steroids and includes their esters. Forum availability is not evidence of legal permission. 21 CFR 1308.13(f): Schedule III anabolic steroids (Official context · Accessed 2026-09-30)

Source context — Compound Experience Thread: 1-Test, DHB, Dihydroboldenone: Anonymous self-reports, deleted identities, unverified preparations and extensive co-use. Partner's female account is secondhand. Reply chains from one writer are one account; brewing advice is not reproduced. Exact publication date was not established from the opened relative timestamps.

Source context — Compounds: DHB versus Tren: Subjective comparative accounts, mixed stacks, unverified products, some deleted writers. A quoted wiki dose is a circulated chart claim, not an initiation instruction. Reposted pain anecdote acknowledged within the thread is not counted as another independent report. Exact date not inferred from relative timestamp.

Source context — Compounds: DHB (Dihydroboldenone): Several steroids, changing testosterone, subjective body composition, unverified blood tests/product identity and confounding dehydration. Pain cannot identify a drug; apparent estrogen changes do not establish aromatase inhibition. No denominator supports prevalence claims.

Source context — 21 CFR 1308.13(f): Schedule III anabolic steroids: Federal controlled-substance context only; does not certify a product, possession circumstance, jurisdiction-specific legality or therapeutic approval.